Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
NRG-GY036
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
- NCT06580314 ↗
- Recruiting
- NRG Oncology
- Standard
We haven't built an HCP commentary report on NRG-GY036 (bevacizumab and olaparib in Fallopian Tube Endometrioid Adenocarcinoma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NRG-GY036 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| YouTube | 10 | |
| Podcasts | 4 | |
| X threads | 4 | |
| Bluesky threads | 2 |
The trial
ClinicalTrials.gov- Official title
- A Phase III Trial of One vs. Two Years of Maintenance Olaparib, With or Without Bevacizumab, in Patients With BRCA1/2 Mutated or Homologous Recombination Deficient (HRD+) Ovarian Cancer Following Response to First Line Platinum-Based Chemotherapy
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Fallopian Tube Endometrioid Adenocarcinoma; Fallopian Tube High Grade Serous Adenocarcinoma; Fallopian Tube Malignant Mixed Mesodermal (Mullerian) Tumor; FIGO Stage III Ovarian Cancer 2014; FIGO Stage IV Ovarian Cancer 2014; Ovarian Carcinoma; Ovarian Carcinosarcoma; Ovarian High Grade Endometrioid Adenocarcinoma; Ovarian High Grade Serous Adenocarcinoma; Primary Peritoneal Carcinosarcoma; Primary Peritoneal Endometrioid Adenocarcinoma; Primary Peritoneal High Grade Serous Adenocarcinoma
- Interventions
- Bevacizumab; Biospecimen Collection; Computed Tomography; Magnetic Resonance Imaging; Olaparib
- Arms
- Arm I (olaparib, bevacizumab) · Active comparator
- Arm II (olaparib, bevacizumab) · Experimental
- Enrollment
- 880 (estimated)
- Primary outcomes
- Progression free survival (PFS) at least 360 days after randomization (PFS360)
- Sponsor
- NRG Oncology with National Cancer Institute (NCI)
- Start
- Mar 12, 2025
- Primary completion
- Dec 31, 2034 (estimated)
- Results posted
- No
- Registry record
- NCT06580314 · updated Aug 7, 2026